Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: Analysis of routinely collected data with emulation of a reference trial (ONTARGET)
Baptiste PJ, Wong AY, Schultze A, Clase CM, Leyrat C, Williamson E, Powell E, Mann JF, Cunnington M, Teo K, Bangdiwala SI, Gao P, Tomlinson L, Wing K (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Book Volume: 193
Pages Range: 1785-1795
Journal Issue: 12
DOI: 10.1093/aje/kwae137
Abstract
Cardiovascular disease is a leading cause of death globally. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), compared in the ONTARGET trial (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial), each prevent cardiovascular disease. However, trial results may not be generalizable, and their effectiveness in underrepresented groups is unclear. Using trial emulation methods within routine-care data to validate findings, we explored the generalizability of ONTARGET results. For people prescribed an ACEi/ARB in the UK Clinical Practice Research Datalink GOLD dataset from January 1, 2001, to July 31, 2019, we applied trial criteria and propensity-score methods to create an ONTARGET trial-eligible cohort. Comparing ARB with ACEi, we estimated hazard ratios for the primary composite trial outcome (cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure) and secondary outcomes. Because the prespecified criteria were met, confirming trial emulation, we then explored treatment heterogeneity among 3 trial-underrepresented subgroups: females, persons aged ≥75 years, and those with chronic kidney disease. In the trial-eligible population (n = 137 155), results for the primary outcome demonstrated similar effects of ARB and ACEi (hazard ratio = 0.97; 95% CI, 0.93-1.01), meeting the prespecified validation criteria. When extending this outcome to trial-underrepresented groups, similar treatment effects were observed by sex, age, and chronic kidney disease. This suggests that ONTARGET trial findings are generalizable to trial-underrepresented subgroups. This article is part of a Special Collection on Pharmacoepidemiology.
Involved external institutions
United Kingdom (GB)
Canada (CA)How to cite
APA:
Baptiste, P.J., Wong, A.Y., Schultze, A., Clase, C.M., Leyrat, C., Williamson, E.,... Wing, K. (2024). Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: Analysis of routinely collected data with emulation of a reference trial (ONTARGET). American Journal of Epidemiology, 193(12), 1785-1795. https://doi.org/10.1093/aje/kwae137
MLA:
Baptiste, Paris J., et al. "Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: Analysis of routinely collected data with emulation of a reference trial (ONTARGET)." American Journal of Epidemiology 193.12 (2024): 1785-1795.
BibTeX: Download